Amundi Grows Holdings in Sanofi (NASDAQ:SNY)

Amundi increased its position in Sanofi (NASDAQ:SNY - Free Report) by 11.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 630,063 shares of the company's stock after acquiring an additional 63,195 shares during the quarter. Amundi's holdings in Sanofi were worth $31,017,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new stake in Sanofi in the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. increased its holdings in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after acquiring an additional 543 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock worth $43,000 after acquiring an additional 313 shares in the last quarter. Sierra Ocean LLC purchased a new stake in Sanofi in the 4th quarter worth approximately $44,000. Finally, Versant Capital Management Inc purchased a new stake in Sanofi in the 4th quarter worth approximately $54,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Down 1.8 %

Shares of SNY opened at $57.69 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The company has a 50 day simple moving average of $53.27 and a two-hundred day simple moving average of $52.81. The firm has a market cap of $146.41 billion, a P/E ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.